Sign Up Today and Learn More About Alector Stock
Invest in or calculate the value of your shares in Alector or other pre-IPO companies through EquityZen's platform.
About Alector Stock
Founded
2013
Headquarters
San Francisco, CA, US
Total Funding
195M
Industries
Science and Engineering, Health Care, Biotechnology
Alector is combining state-of-the-art antibody technology and recent discoveries in neuroimmunology and human genetics to develop novel therapeutics for Alzheimer’s disease, other forms of dementia, and mechanistically related neurodegenerative disorders. Alector’s strategy is to efficiently generate and validate antibody drugs with unique functional properties that engage key disease-altering targets. This approach is enabled by a strategic alliance with Adimab, the industry leader in discovery and optimization of antibody therapeutics. Alector is currently developing leads for 4 major targets and anticipates taking 2 of these through pre-clinical development and IND enabling studies within 24 months. Alector has incorporated a highly integrated and lean biotechnology structure with extensive outsourcing that supports core scientific and management teams.
Alector Management
Leadership team at Alector
Founder, President & Chief Executive Officer
Arnon Rosenthal
Founder & Chairman of the Board
Tillman Gerngross
Join now and verify your accreditation status to gain access to:
- Alector Current Valuation
- Alector Stock Price
- Alector Management
- Available deals in Alector and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Alector Cap Table and Funding History by Share Class and Liquidity Preferences
- Alector Revenue and Financials
- Alector Highlights
- Alector Business Model
- Alector Risk Factors
- Alector Research Report from SACRA Research
Trading Alector Stock
How to invest in Alector stock?
Accredited investors can buy pre-IPO stock in companies like Alector through EquityZen funds. These investments are made available by existing Alector shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Alector stock?
Shareholders can sell their Alector stock through EquityZen's private company marketplace. EquityZen's network includes over 380K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 47K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."